Possible Synergy between Recombinant Factor VIIa and Prothrombin Complex Concentrate in Hemophilia Therapy
Possible Synergy between Recombinant Factor VIIa and Prothrombin Complex Concentrate in Hemophilia Therapy
复制标题
重组因子 VIIa 和凝血酶原复合物浓缩物在血友病治疗中可能存在的协同作用
DOI:
10.1055/s-0037-1613155
复制
发表时间:
2002
影响因子:
6.7
通讯作者:
G. Nelsestuen
中科院分区:
文献类型:
--
作者:
N. Key;B. Christie;N. Henderson;G. Nelsestuen
Summary Recombinant factor VIIa (rFVIIa; Novoseven™) is used for treatment of hemophilia patients with inhibitors. There are poorly defined differences in clinical responsiveness between individuals. Prior to licensure in the United States, rFVIIa was available through the compassionate use program, during which two patients described in this study demonstrated an excellent response. More recently, one of these individuals showed a sub-optimal response to rFVIIa. One possible explanation for different treatment outcomes was sequential therapy with prothrombin complex concentrates (PCC) followed by rFVIIa in the compassionate use program. In support of this, an in vitro test showed that this patient had an exceptionally strong response to rFVIIa when it was added to whole blood after the patient received PCC therapy. Results with other patients supported this hypothesis. With further evaluation, a therapeutic approach combining sequential PCC and rFVIIa may prove useful for treatment of bleeding refractory to either agent used alone.
DOI:
10.1159/000217229
发表时间:
1996
期刊:
Haemostasis
影响因子:
--
作者:
Rao,LV;Rapaport,SI
通讯作者:
Rapaport,SI
DOI:
--
发表时间:
1998
期刊:
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
影响因子:
--
作者:
Monroe,DM;Hoffman,M;Oliver,JA;Roberts,HR
通讯作者:
Roberts,HR
DOI:
10.1172/jci116691
发表时间:
1993
期刊:
The Journal of clinical investigation
影响因子:
--
作者:
tenCate,H;Bauer,KA;Levi,M;Edgington,TS;Sublett,RD;Barzegar,S;Kass,BL;Rosenberg,RD
通讯作者:
Rosenberg,RD